Get Connected:

The MD Magazine Hypertriglyceridemia condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

How Pulmonary Function Relates to Lipoproteins
There is a positive association of measures of pulmonary function with lipoprotein a [Lp(a)] in older adults who live in a community setting, according to a recent study.
The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)— approved in July in the US — lowered cholesterol in patients with familial hypercholesterolemia to levels “unreachable with statins” researchers said at the European Society of Cardiology meeting in London, UK.
Cardiovascular disease is the most common comorbidity in patients with rheumatoid arthritis (RA) and the reason behind it may have finally been identified.
The US Food and Drug Administration on Friday approved the first cholesterol-lowering treatment in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) project, a 4-year Centers for Medicare and Medicaid Services-sponsored demonstration project, showed that a telemedicine intervention can improve glycemic, lipid, and blood pressure control.
Friday could be a big day for cardiologists. The FDA is due to rule July 24 on what could be the first available PCSK9 inhibitor, one of a new class of cholesterol-lowering agents meant to help patients who cannot get their LDL levels low enough with statins. New York City cardiologist David Vorchheimer, MD. talks about his hopes for the new drugs, and a few concerns
Tocilizumab treated rheumatoid arthritis patients are at an increased risk for major adverse cardiovascular events, according to a study published in Arthritis & Rheumatology.

Most Popular

$vacMongoViewPlus$ $vAR$